SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Geschlossen

1.415 -2.48

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.4060000000000001

Max

1.415

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.009
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-43M 954M
Vorheriger Eröffnungskurs	3.9
Vorheriger Schlusskurs	1.415

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Nov. 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

21. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Nov. 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21. Nov. 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21. Nov. 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21. Nov. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21. Nov. 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21. Nov. 2025, 19:44 UTC

Ergebnisse

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21. Nov. 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21. Nov. 2025, 19:27 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

21. Nov. 2025, 19:27 UTC

Market Talk

Ergebnisse

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21. Nov. 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21. Nov. 2025, 18:44 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21. Nov. 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21. Nov. 2025, 18:34 UTC

Market Talk

Ergebnisse

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21. Nov. 2025, 18:28 UTC

Ergebnisse

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. Nov. 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21. Nov. 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21. Nov. 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21. Nov. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Nov. 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21. Nov. 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21. Nov. 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21. Nov. 2025, 16:35 UTC

Akquisitionen, Fusionen, Übernahmen

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21. Nov. 2025, 16:09 UTC

Ergebnisse

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. Nov. 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21. Nov. 2025, 15:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Nov. 2025, 15:23 UTC

Market Talk

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21. Nov. 2025, 15:17 UTC

Market Talk

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.